Positive Quality Intervention: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Description: This PQI will discuss effective management of adverse effects of sorafenib in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.

Background: Hepatocellular carcinoma (HCC) is associated with a high mortality rate and historically the treatment options have been limited. Prior to 2018, sorafenib was the only Food and Drug Administration approved targeted therapy for the initial treatment of unresectable HCC in patients diagnosed with late stage or metastatic disease. Second-line treatment options, though growing in number, have limited and at times conflicting survival data; and all factors of options should be considered. A retrospective study of the RESORCE trial ascertained median time from start of sorafenib to death in patients receiving sequential therapy to regorafenib. Exploratory analysis revealed time from sorafenib initiation to death as 26 months for regorafenib patients vs. 19.2 months for placebo patients.

PQI Process: Upon receipt of a prescription for sorafenib:

- Obtain CBC with differential, metabolic panel including magnesium and phosphorus, liver function tests, lipase and amylase prior to starting therapy and then monthly until labs have stabilized
- Consider obtaining thyroid stimulating hormone level at baseline, every 4 weeks for 4 months, and then every 2-3 months thereafter
- Monitor blood pressure at baseline and weekly during the first 6 weeks of sorafenib, and then monitor blood pressure, utilizing clinic appointments and treat any developing hypertension as needed
- Treatment associated hypertension and dermatologic toxicity are managed with dose interruptions and reductions. Grade 1 dermatologic toxicity may not require dosage adjustments (see table 3 for dose reductions due to toxicity)
- Consider proactively discussing 2nd line treatment options following progression or intolerance

If regorafenib is considered for 2nd line tyrosine kinase inhibitor transitioning

- Ensure recovery from sorafenib mediated adverse effects and that patient did not permanently discontinue sorafenib due to toxicity or inability to tolerate doses
  - RESORCE trial required that patients be able to tolerate at least 400 mg a day of sorafenib for 20 days of the last 28 days prior to withdrawal to be eligible
- Determine Child-Pugh Class status and make appropriate recommendation for therapy
- If underlying hypertension exists or developed while on sorafenib, ensure appropriate blood pressure control prior to starting regorafenib
- Refer to Regorafenib (Stivarga®) In the Treatment of Hepatocellular Carcinoma PQI for managing adverse effects

Patient Centered Activities:
Counseling for sorafenib

- Provide patient Oral Chemotherapy Education (OCE) sheet and Oral Chemotherapy Education Supplemental sheets

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 10.28.21
• Counsel patient on the signs and symptoms of hand-foot syndrome and other dermatologic side effects  
  o Refer to Medication Induced Hand-Foot Syndrome PQI
• Counsel on appropriate management of chemotherapy induced diarrhea  
  o Refer to Oncolytic Induced Diarrhea PQI
• Counsel on measuring blood pressure weekly at home (first 6 weeks) and instruct to report blood pressures > 140/90 mmHg
• Dose adjustments for baseline hepatic and renal dysfunction have been recommended based on a phase I pharmacokinetic study and are included in Table 1 and 2\textsuperscript{15}

**Counseling for regorafenib**

• Provide patient Oral Chemotherapy Education (OCE) sheet and Oral Chemotherapy Education Supplemental sheet
• Utilize principles within Regorafenib (Stivarga\textsuperscript{®}) In the Treatment of Hepatocellular Carcinoma PQI
• Counsel patient on the signs and symptoms of hand-foot syndrome and other dermatologic side effects  
  o Refer to Medication Induced Hand-Foot Syndrome PQI

**Supplemental Information:**

### Table 1: Dose Adjustments for Baseline Hepatic Dysfunction\textsuperscript{15}*

<table>
<thead>
<tr>
<th>Degree of Hepatic Impairment</th>
<th>Criteria</th>
<th>Sorafenib Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Bilirubin &gt;1 to ≤1.5 times ULN and/or AST &gt;ULN</td>
<td>400 mg twice daily</td>
</tr>
<tr>
<td>Moderate</td>
<td>Bilirubin &gt;1.5 to ≤3 times ULN; any AST</td>
<td>200 mg twice daily</td>
</tr>
<tr>
<td>Severe</td>
<td>Albumin &lt;2.5 g/dL with any bilirubin/AST</td>
<td>200 mg once daily</td>
</tr>
<tr>
<td></td>
<td>Bilirubin &gt;3 to 10 x ULN with any AST</td>
<td>No tolerable dose identified</td>
</tr>
</tbody>
</table>

*Reference used differs slightly from sorafenib prescribing information reference

### Table 2: Dose Adjustments for Baseline Renal Dysfunction\textsuperscript{15}

<table>
<thead>
<tr>
<th>Baseline Creatinine Clearance</th>
<th>Sorafenib Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>40-59 mL/min</td>
<td>400 mg twice daily</td>
</tr>
<tr>
<td>20-39 mL/min</td>
<td>200 mg twice daily</td>
</tr>
<tr>
<td>&lt; 20 mL/min</td>
<td>Unable to define dose</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>200 mg once daily</td>
</tr>
</tbody>
</table>

### Table 3: Dose Reduction Levels for Adverse Effects*

<table>
<thead>
<tr>
<th>Dose Reduction</th>
<th>Sorafenib Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting</td>
<td>400 mg twice daily</td>
</tr>
<tr>
<td>1</td>
<td>200 mg twice daily</td>
</tr>
<tr>
<td>2</td>
<td>200 mg once daily or 400 mg every other day</td>
</tr>
<tr>
<td>3</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

**Patient Assistance**

Sorafenib patients can utilize the REACH support program while on therapy

• Nurse counselors are available for answering questions and providing patient education including Patient Starter Kits
• Service counselors are available to discuss patient access services including co-pay assistance

**Important notice:** NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 10.28.21
**References:**


**Important notice:** NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 10.28.21